No Data
Statistics on the abnormal changes in the Hong Kong Stock Connect proportion | December 10
Statistics of the abnormal changes in the proportion of Zhitong Hong Kong Stock Connect | December 9, 2024.
ImmuneOnco Biopharmaceuticals Gets Phase 2 Trial Approval for Autoimmune Disease Drug
I-Mab BioPharma-B (01541): IMM0306 has been approved by the National Medical Products Administration for phase II clinical trials for the treatment of lupus nephritis.
Yiming Anco-B (01541) announced that the group has been approved by the National Medical Products Administration of the People's Republic of China to proceed...
Express News | ImmuneOnco Biopharmaceuticals Shanghai - Approval by Nmpa for Phase II Clinical Trial of Imm0306 for Treatment of Lupus Nephritis
E-miniangu-B (01541.HK) plans to allocate a total of 33.15 million new H-shares, with a total fundraising of 0.234 billion Hong Kong dollars.
KeLongHui November 21st | Yiming Ounc-B (01541.HK) issued an announcement. On November 21, 2024, the company entered into a placing agreement with China International Capital Corporation (as the placing agent). According to this, the placing agent has agreed to act as the company's exclusive placing agent and will endeavor to persuade subscribers to subscribe for a total of 33.15 million new H shares at a placing price of HK$7.05 per share in accordance with the terms set out in the placing agreement and subject to the conditions set out in such agreement. The placing shares represent approximately 8.86% and 9.50% of the company's issued share capital and total issued H shares as of the date of this announcement, and of the shares issued
Express News | ImmuneOnco Biopharmaceuticals Shanghai Inc - Placing of New H Shares
